Abiramale 250 – Elevating Standards in Prostate Cancer
🚀Product Launch: Abiramale 250 We are proud to introduce Abiramale 250 contains Abiraterone Acetate 250 mg, an advanced androgen-biosynthesis inhibitor designed to improve outcomes in metastatic castration-resistant prostate cancer (mCRPC).By selectively inhibiting the CYP17 enzyme, Abiramale 250 reduces androgen production from the testes, adrenal glands, and tumor tissue—helping slow disease progression and enhance patient survival. Designed…
